Literature DB >> 16053254

Design and analysis of drug combination experiments.

Roel Straetemans1, Timothy O'Brien, Luc Wouters, Jacky Van Dun, Michel Janicot, Luc Bijnens, Tomasz Burzykowski, Marc Aerts.   

Abstract

In this paper we present and discuss a novel, simple and easy to implement parametric modeling approach to assess synergy. An extended three parameter log-logistic model is used to analyse the data and calculate confidence intervals of the interaction indices. In addition the model corrects for the bias due to plate-location effects. The analysis is performed with PROC NLMIXED and SAS-code is provided. The approach is illustrated using data coming from an oncology study in which the inhibition effect of a combination of two compounds is studied using 96-well plates and a fixed-ratio design.

Mesh：

Substances：

Year:  2005        PMID： 16053254     DOI： 10.1002/bimj.200410124

Source DB:  PubMed          Journal:  Biom J        ISSN： 0323-3847            Impact factor:   2.207


  27 in total

Review 1.  A few specialized issues that should be focused on anti-HIV drug evaluation in vitro.

Authors:  Dao-min Zhuang; Jing-yun Li
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

2.  Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

Authors:  Adam D Steg; Ashwini A Katre; Blake Goodman; Hee-Dong Han; Alpa M Nick; Rebecca L Stone; Robert L Coleman; Ronald D Alvarez; Gabriel Lopez-Berestein; Anil K Sood; Charles N Landen
Journal:  Clin Cancer Res       Date:  2011-07-13       Impact factor: 12.531

3.  A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.

Authors:  Baptiste Ronan; Odile Flamand; Lionel Vescovi; Christine Dureuil; Laurence Durand; Florence Fassy; Marie-France Bachelot; Annabelle Lamberton; Magali Mathieu; Thomas Bertrand; Jean-Pierre Marquette; Youssef El-Ahmad; Bruno Filoche-Romme; Laurent Schio; Carlos Garcia-Echeverria; Hélène Goulaouic; Benoit Pasquier
Journal:  Nat Chem Biol       Date:  2014-10-19       Impact factor: 15.040

4.  Design issues for population growth models.

Authors:  J López Fidalgo; I M Ortiz Rodríguez; Weng Kee Wong
Journal:  J Appl Stat       Date:  2011-03-01       Impact factor: 1.404

5.  Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

Authors:  Vincent Chau; S Kyun Lim; Wei Mo; Chiachi Liu; Amish J Patel; Renée M McKay; Shuguang Wei; Bruce A Posner; Jef K De Brabander; Noelle S Williams; Luis F Parada; Lu Q Le
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

6.  Triple combination of siRNAs targeting TGFβ1, TGFβR2, and CTGF enhances reduction of collagen I and smooth muscle actin in corneal fibroblasts.

Authors:  Sriniwas Sriram; Paulette Robinson; Liya Pi; Alfred S Lewin; Gregory Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-17       Impact factor: 4.799

7.  Minimizing human infection from Escherichia coli O157:H7 using GUMBOS.

Authors:  Marsha R Cole; Min Li; Ravirajsinh Jadeja; Bilal El-Zahab; Daniel Hayes; Jeffery A Hobden; Marlene E Janes; Isiah M Warner
Journal:  J Antimicrob Chemother       Date:  2013-02-26       Impact factor: 5.790

8.  Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2013-03-07       Impact factor: 1.894

9.  Cytokine combination therapy prediction for bone remodeling in tissue engineering based on the intracellular signaling pathway.

Authors:  Xiaoqiang Sun; Jing Su; Jiguang Bao; Tao Peng; Le Zhang; Yuanyuan Zhang; Yunzhi Yang; Xiaobo Zhou
Journal:  Biomaterials       Date:  2012-08-19       Impact factor: 12.479

10.  Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.

Authors:  Katty Terrazas-Aranda; Yven Van Herrewege; Daria Hazuda; Paul Lewi; Roberta Costi; Roberto Di Santo; Andrea Cara; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.